BPGbio to Present Novel E2-based Targeted Protein Degradation Program at TPD and Induced Proximity Summit

BPGbio to Present Novel E2-based Targeted Protein Degradation Program at TPD and Induced Proximity Summit

BPGbio, Inc., a leading biology-first, AI-powered, clinical stage biopharma focused on mitochondrial biology and protein homeostasis, today announced its participation in then 7th Annual Targeted Protein Degradation (TPD) and Induced Proximity Summit, in Boston. BPGbio executive Vivek K. Vishnudas, Ph.D., Chief Technology Officer and R&D Site Head, will present a session titled, "A Novel & Differentiated Approach to Targeted Protein Degradation – Leveraging the Ubiquitin Conjugating Enzyme (E2) Family” on the first day of the conference, October 28.

The session will highlight latest developments in the company’s protein homeostasis program as BPGbio continues to advance potential first-in-class E2-based therapeutics in both neurology and oncology. Key points of the presentation include:

E2 enzymes have historically been considered challenging to design ligands for modulation
BPGbio was able to achieve strong and specific binding by targeting a modified E2 complex, enabling a novel and differentiated approach to targeted protein degradation that is independent of CRBN and VHL
BPGbio has identified ofE2-based ER ? degrader and several other undisclosed targets, leveraging the inherent E2 advantages including higher expression and lower mutation

“Our pioneering E2-based protein degradation is reshaping the TPD landscape, setting us apart from the more traditional E3 approaches,” said Dr. Vishnudas. “By harnessing the power of the ubiquitin conjugating enzyme (E2) family, we’re unlocking entirely new therapeutic modalities. We are excited to collaborate with the biopharma community as we push the boundaries of this revolutionary field and bring forward novel solutions to address unmet medical needs.”

TPD has recently emerged as a game-changing approach to address proteins that have been difficult to target or protein target that yield limited clinical benefits through traditional small molecule inhibition. While most conventional TPD strategies rely on the use of E3 ligases, new research has shown that E2 proteins—once considered elusive—can be harnessed for effective and precise protein degradation, opening new avenues for therapeutic intervention.

BPGbio’s TPD program is at the forefront of this breakthrough, utilizing E2s to drive the development of innovative bifunctional degraders and monovalent molecular glues, opening new frontiers in drug discovery.

In addition to utilizing E2s, the BPGbio’s protein homeostasis program features a proprietary library of more than 1,000 Ro3 fragments discovered by BPGbio that are potential ligands and seed compounds to a variety of E2 targets, proprietary ternary structures, a computational tool kit for E2 ligand design, and assays for rapidly attaining selectivity and specificity.

About BPGbio

BPGbio is a leading biology-first AI-powered clinical stage biopharma focused on mitochondrial biology and protein homeostasis. The company has a deep pipeline of AI-developed therapeutics spanning oncology, rare disease and neurology, including several in late-stage clinical trials. BPGbio’s novel approach is underpinned by NAi, its proprietary Interrogative Biology Platform, protected by over 400 US and international patents; one of the world’s largest clinically annotated non-governmental biobanks with longitudinal samples; and exclusive access to the most powerful supercomputer in the world. With these tools, BPGbio is redefining how patient biology can be modeled using bespoke Bayesian AI specifically designed for solving large-scale biology challenges. Headquartered in greater Boston, the company is at the forefront of a new era in medicine, combining biology, multi-modal data, and AI to transform the way we understand, diagnose, and treat disease. For more information, visit www.bpgbio.com.